Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action

Faruqi & Faruqi, LLP reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).

The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the true state of Regeneron's Phase III Fianlimab-Libtayo Study was problematic, specifically that its preliminary statistical assumptions were fundamentally flawed, the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and the trial would ultimately fail to reach statistical significance on its primary endpoint.

Investors who purchased or acquired Regeneron (NASDAQ: REGN) between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Following the alleged corrective disclosures, Regeneron shares fell approximately 9.8% on May 18, 2026.